Celiac Disease Foundation Presents at the International Celiac Disease Symposium in New Delhi, India
iCureCeliac® is the only public celiac disease patient registry designed to help researchers better understand, and ultimately cure, celiac disease and non-celiac gluten/wheat sensitivity. iCureCeliac® allows patients to contribute medical information and their experiences living with celiac disease and non-celiac gluten/wheat sensitivity to advance life-changing initiatives in research, education, and advocacy. Your participation in iCureCeliac® will help […]
The pharmaceutical industry, the Food and Drug Administration, and disease advocacy organizations like Celiac Disease Foundation (CDF) are all seeking meaningful patient engagement in the drug research and development process. There is considerable evidence that when patients are active participants in disease research, the drug development process is not only more cost and time efficient, […]
Celiac Disease Foundation recently administered a survey to gauge community interest in using a simple in-home urine or stool test to monitor gluten intake. Through our iCureCeliac® patient registry, we have found that 53% of people with celiac disease continue to experience symptoms while on a strict gluten-free diet. The most common reason for persistent […]
Researchers and clinicians are continually evaluating diagnostic options to better identify those who live with celiac disease, and improve overall health and quality of life.
Celiac Disease Foundation (CDF) and the Gluten Intolerance Group (GIG) are proud to announce a partnership that will improve the health and well-being of the celiac disease and gluten-free communities. n order to create the most comprehensive nonprofit
The CDF Clinical Trial Finder will make it easier for patients with celiac disease and non-celiac gluten/wheat sensitivity to enroll in clinical trials, enabling patients to better engage with medical research and accelerate development of drugs and treatments.
For decades, Celiac Disease Foundation (CDF) has advocated for more widespread diagnostic testing for symptomatic celiac disease patients and their first-degree family members (parent, child, sibling) to ease much of the needless suffering caused by the disease.
At the March 9 and 10, 2017 Genetic Alliance Conference, Celiac Disease Foundation worked to determine best strategies to help grow our iCureCeliac® patient registry, and to encourage patients and their family members to engage in the research process to influence the future of celiac disease research toward treatments and a cure.
ImmusanT, a Cambridge, MA-based biotechnology company, has announced that Nexvax2®, an immunotherapy drug designed to protect celiac disease patients from gluten exposure, has successfully completed a Phase 1b clinical trial and is advancing to a Phase 2 trial. Currently, strict, lifetime adherence to a gluten-free diet is the only disease management protocol for celiac disease […]